<DOC>
	<DOCNO>NCT00061360</DOCNO>
	<brief_summary>Severe aplastic anemia ( SAA ) life-threatening bone marrow failure disorder characterize pancytopenia hypocellular bone marrow . Allogeneic bone marrow transplantation immunosuppressive treatment anti-thymocyte globulin ( ATG ) cyclosporine ( CsA ) dramatically change natural course illness , 5 year survival 75 % patient undergo either treatment . Since patient suitable candidate hematopoietic stem cell transplantation ( HSCT ) due advanced age lack histocompatible sibling , effort NHLBI focus improve immunosuppression treatment order improve response rate , survival , decrease relapse . In experience 122 patient treat NHLBI combination ATG cyclosporine , one quarter one third respond ; 50 % responder relapse ; 5 year survival correlate robustness blood cell count improvement 3 month ( reticulocyte platelet count great equal 50,000 /uL ) . Why patient respond initially others relapse unclear . Autoreactive T cell may resistant effect ATG/CsA ( nonresponders ) , others residual autoreactive T cell expand post-treatment leading hematopoietic stem cell destruction recurrent pancytopenia ( relapse ) . Therefore , novel immunosuppressive regimen increase response rate hematologic recovery 3 month decrease relapse rate need . An ongoing NHLBI trial , close complete accrual , added mycophenolate mofetil ( MMF ) total 18 month standard ATG + CsA attempt reduce relapse rate cyclosporine discontinue . Preliminary result disappointing , marked reduction relapse among patient receive MMF . Sirolimus ( rapamycin , Rapamune , RAPA ) novel immunosuppressive agent , act synergistically cyclosporine block T cell activation CsA-resistant pathway . The potentiation combination CsA-RAPA establish vitro clinical setting , mainly islet cell solid organ transplantation . The significant increase response rate see addition CsA ATG indicate inhibitory effect T lymphocytes important block autoreactive T cell aplastic anemia . The combination CsA-RAPA may block activate autoreactive T cell therefore lead improved response rate ( survival ) decrease relapse rate . This prospective randomize phase II study investigate two different immunosuppressive regimen patient severe aplastic anemia receive prior immunosuppressive therapy . One arm receive ATG + CsA addition sirolimus 6 month , second arm receive standard ATG + CsA 6 month follow slow taper CsA 25 % dose reduction every 3 month subsequent 18 month . This trial determine effectiveness sirolimus patient aplastic anemia well role cyclosporine taper prevent relapse . Primary endpoint longer meeting criterion severe aplastic anemia secondary endpoint relapse , robustness hematologic recovery 3 month , survival , clonal evolution PNH , myelodysplasia acute leukemia . 10/11/2005 . The Sirolimus ( Rapamune ) arm trial stop lack efficacy . The study continue single arm study establish slow taper CsA prevent relapse rate initial standard treatment ATG follow CsA six month ... .</brief_summary>
	<brief_title>Improving Immunosuppressive Treatment Patients With Severe Aplastic Anemia</brief_title>
	<detailed_description>Severe aplastic anemia ( SAA ) life-threatening bone marrow failure disorder characterize pancytopenia hypocellular bone marrow . Allogeneic bone marrow transplantation immunosuppressive treatment anti-thymocyte globulin ( ATG ) cyclosporine ( CsA ) dramatically change natural course illness , 5 year survival 75 % patient undergo either treatment . Since patient suitable candidate hematopoietic stem cell transplantation ( HSCT ) due advanced age lack histocompatible sibling , effort NHLBI focus improve immunosuppression treatment order improve response rate , survival , decrease relapse . In experience 122 patient treat NHLBI combination ATG cyclosporine , one quarter one third respond ; 50 % responder relapse ; 5 year survival correlate robustness blood cell count improvement 3 month ( reticulocyte platelet count great equal 50,000 /uL ) . Why patient respond initially others relapse unclear . Autoreactive T cell may resistant effect ATG/CsA ( nonresponders ) , others residual autoreactive T cell expand post-treatment leading hematopoietic stem cell destruction recurrent pancytopenia ( relapse ) . Therefore , novel immunosuppressive regimen increase response rate hematologic recovery 3 month decrease relapse rate need . An ongoing NHLBI trial , close complete accrual , added mycophenolate mofetil ( MMF ) total 18 month standard ATG + CsA attempt reduce relapse rate cyclosporine discontinue . Preliminary result disappointing , marked reduction relapse among patient receive MMF . Sirolimus ( rapamycin , Rapamune , RAPA ) novel immunosuppressive agent , act synergistically cyclosporine block T cell activation CsA-resistant pathway . The potentiation combination CsA-RAPA establish vitro clinical setting , mainly islet cell solid organ transplantation . The significant increase response rate see addition CsA ATG indicate inhibitory effect T lymphocytes important block autoreactive T cell aplastic anemia . The combination CsA-RAPA may block activate autoreactive T cell therefore lead improved response rate ( survival ) decrease relapse rate . This prospective randomize phase II study investigate two different immunosuppressive regimen patient severe aplastic anemia receive prior immunosuppressive therapy . One arm receive ATG + CsA addition sirolimus 6 month , second arm receive standard ATG + CsA 6 month follow slow taper CsA 25 % dose reduction every 3 month subsequent 18 month . This trial determine effectiveness sirolimus patient aplastic anemia well role cyclosporine taper prevent relapse . Primary endpoint longer meeting criterion severe aplastic anemia secondary endpoint relapse , robustness hematologic recovery 3 month , survival , clonal evolution PNH , myelodysplasia acute leukemia . 10/11/2005 . The Sirolimus ( Rapamune ) arm trial stop lack efficacy . The study continue single arm study establish slow taper CsA prevent relapse rate initial standard treatment ATG follow CsA six month . 3/2/2006 . The protocol close new accrual .</detailed_description>
	<mesh_term>Anemia</mesh_term>
	<mesh_term>Anemia , Aplastic</mesh_term>
	<mesh_term>Immunosuppressive Agents</mesh_term>
	<mesh_term>Sirolimus</mesh_term>
	<mesh_term>Everolimus</mesh_term>
	<mesh_term>Cyclosporins</mesh_term>
	<mesh_term>Cyclosporine</mesh_term>
	<criteria>INCLUSION CRITERIA : Severe aplastic anemia confirm NIH : 1. . Bone marrow cellularity le 30 % ( exclude lymphocyte ) 2. . At least two follow : Absolute neutrophil count le 500/ uL ; Platelet count le 20,000/ uL ; Absolute reticulocyte count le 60,000/ uL Age great equal 2 year old Weight great 12 kg EXCLUSION CRITERIA : Serum creatinine great 2.5 mg/dL Underlying carcinoma ( except local cervical , basal cell , squamous cell ) Prior immunosuppressive therapy ATG , ALG , high dose cyclophospamide . Current pregnancy lactation unwillingness take oral contraceptive use effective method birth control . Diagnosis Fanconi anemia congenital bone marrow failure syndromes Evidence clonal disorder cytogenetics . Patients super severe neutropenia ( ANC le 200/uL ) exclude result cytogenetics available pending . Underlying immunodeficiency state include seropositivity HIV Inability understand investigational nature study give inform consent Moribund status concurrent hepatic , renal , cardiac , neurologic , pulmonary , infectious , metabolic disease severity would preclude patient ability tolerate protocol therapy , death within 710 day likely .</criteria>
	<gender>All</gender>
	<minimum_age>2 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 25, 2016</verification_date>
	<keyword>Bone Marrow Failure</keyword>
	<keyword>Cyclosporine</keyword>
	<keyword>Anti Thymocyte Globulin</keyword>
	<keyword>Severe Aplastic Anemia</keyword>
</DOC>